Amivantamab in Adenoid Cystic Carcinoma

Phase II Study to Evaluate Amivantamab in Recurrent and Metastatic Adenoid Cystic Carcinoma

The purpose of the study is to determine if treatment with amivantamab will be efficacious in patients with recurrent and metastatic adenoid cystic carcinoma.

Study Overview

• Status: Active, not recruiting
• Conditions: Salivary Gland Cancer
• Intervention / Treatment: Drug: Amivantamab

Detailed Description

ACC is a rare cancer of salivary glands and other glandular tissue. It is slow growing and is usually treated with surgery and radiation. However, this type of cancer tends to have a high rate of recurrence and metastatic spread, which develops over several years. We hypothesize that amivantamab, a bispecific EGFR and MET inhibitor will be efficacious in ACC. Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).

• Study Type: Interventional
• Enrollment (Actual): 21
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • California
    • La Jolla, California, United States, 92093
      • UC San Diego Moores Cancer Center
  • Massachusetts
    • Boston, Massachusetts, United States, 02215
      • Dana Farber Cancer Institute
  • Michigan
    • Ann Arbor, Michigan, United States, 48109
      • Rogel Cancer Center - University of Michigan Health
  • Missouri
    • St Louis, Missouri, United States, 63130
      • Washington University - School of Medicine in St. Louis
  • Ohio
    • Cincinnati, Ohio, United States, 45219
      • University of Cincinnati Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Pathologically or cytologically confirmed adenoid cystic carcinoma. Non-salivary gland primary sites are allowed.
2. Recurrent and/or metastatic disease not amenable to other curative intent therapy. Patients must have had evidence of progressive disease by RECIST v1.1 within 6 months of study enrollment.
3. Presence of measurable disease as defined by RECIST v1.1
4. Age ≥18 years.
5. ECOG performance status, see Appendix A).
6. Patients must have adequate organ and marrow function
7. Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression in the last 4weeks.
8. Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy.
9. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
10. Before enrollment, a participant must be (as defined in Appendix 2: Contraceptive Guidance and Collection of Pregnancy Information)
11. A participant of childbearing potential must have a negative serum (b-human chorionic gonadotropin [b-hCG]) at screening and within 72 hours of the first dose of study treatment and must agree to further serum or urine pregnancy tests during the study.
12. A participant must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for 6 months after receiving the last dose of study drug.
13. A participant must wear a condom when engaging in any activity that allows for passage of ejaculate to another person during the study and for 6 months after receiving the last dose of study treatment. A participant who is sexually active with a partner of childbearing potential must agree to use a condom with spermicidal foam/gel/film/cream/suppository and his partner must also be practicing a highly effective method of contraception (i.e., established use of oral, injected or implanted hormonal methods of contraception; placement of an intrauterine device [IUD] or intrauterine system [IUS]). If the subject is vasectomized, they must still use a condom (with or without spermicide) for prevention of passage of exposure through ejaculation, but their partner is not required to use contraception.
14. The subject must also not donate sperm during the study and for 6 months after receiving the last dose of study drug.
15. Ability to understand and the willingness to sign a written informed consent document.
16. Participant must be willing and able to adhere to the lifestyle restrictions specified in this protocol.

Exclusion Criteria

1. History of allergy or intolerance to study drug components.
2. Prior use of amivantamab.

3 .Patients who have had chemotherapy or immunotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study. Palliative radiotherapy is allowed and does not require washout as long as it does not include a target lesion.

4. Positive hepatitis B (hepatitis B virus [HBV]) surface antigen (HBsAg) Note: Subjects with a prior history of HBV demonstrated by positive hepatitis B core antibody are eligible if they have at Screening 1) a negative HBsAg and 2) a HBV DNA (viral load) below the lower limit of quantification, per local testing. Subjects with a positive HBsAg due to recent vaccination are eligible if HBV DNA (viral load) is below the lower limit of quantification, per local testing.

5. Positive hepatitis C antibody (anti-HCV). Note: Subjects with a prior history of HCV, who have completed antiviral treatment and have subsequently documented HCV RNA below the lower limit of quantification per local testing are eligible.

6.Participant is positive for human immunodeficiency virus (HIV), with 1 or more of the following:

1. Receiving ART that may interfere with study treatment (consult sponsor for review of medication prior to enrollment)
2. CD4 count <350 at screening
3. AIDS-defining opportunistic infection within 6 months of start of screening
4. Not agreeing to start ART and be on ART>4 weeks plus having HIV viral load<400 copies/mL at end of 4-week period (to ensure ART is tolerated and HIV controlled).

7.Other clinically active infectious liver disease.

8. Participant has active cardiovascular disease including, but not limited to:

• A medical history of deep vein thrombosis or pulmonary embolism within 1 month prior to enrollment or any of the following within 6 months prior to enrollment: myocardial infarction, unstable angina, stroke, transient ischemic attack, coronary/peripheral artery bypass graft, or any acute coronary syndrome. Clinically non-significant thrombosis, such as non-obstructive catheter-associated thrombus(clots), or incidental or asymptomatic pulmonary embolism are not exclusionary.
• Participant has a significant genetic predisposition to venous thromboembolic(VTE) events such as Factor V Leiden.
• Participant has a prior history of VTE and is not on appropriate therapeutic anticoagulation as per NCCN or local guidelines.
• Uncontrolled (persistent) hypertension: systolic blood pressure >160 mm Hg;diastolic blood pressure >100 mm Hg.

• Congestive heart failure (CHF), defined as New York Heart Association (NYHA)class III-IV or hospitalization for CHF (any NYHA class; refer to Appendix 3:New York Heart Association Criteria) within 6 months of starting drug.

  9. Subject has uncontrolled illness, including but not limited to:

• Uncontrolled diabetes
• Ongoing or active infection (includes infection requiring treatment with antimicrobial therapy [participants will be required to complete antibiotics 1 week prior to starting study treatment] or diagnosed or suspected viral infection).
• Active bleeding diathesis
• Impaired oxygenation requiring continuous oxygen supplementation (e.g., due to medical condition requiring chronic continuous oxygen therapy).
• Psychiatric illness/social situation that would limit compliance with study requirements.

• Any ophthalmologic condition that is clinically unstable

  10. Active or past medical history of Interstitial lung disease (ILD)/pneumonitis, including drug-induced or radiation ILD/ pneumonitis.

  11. Participant had major surgery excluding placement of vascular access or tumor biopsy or had significant traumatic injury within 4 weeks before enrollment, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study. Note: Participants with planned surgical procedures to be conducted under local anesthesia may participate.

  12. Immune-mediated rash from checkpoint inhibitors that has not resolved prior to enrollment.

  13. Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia or Grade 2 neuropathy.

  14. Patients who are receiving any other investigational agents. Patients who have received other investigational agents previously who are no longer receiving these investigational agents may be eligible at the discretion of the PI. A 30 day washout from last dose of previous anticancer drug is required.

  15. Pregnant women are excluded from this study. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with breastfeeding should be discontinued if the mother is treated with amivantamab.

  16. Judgment by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions, and requirements.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Amivantamab; Amivantamab weekly for the first cycle and biweekly thereafter.	Drug: Amivantamab; Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Response Rate Measured by RECIST Criteria	To determine the overall response rate in patients with recurrent and metastatic adenoid cystic carcinoma treated with amivantamab. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR."	2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression Free Survival -Measured as Time of Treatment Allocation to Confirmed Progressive Disease or Death.	To determine the progression free survival with recurrent and metastatic adenoid cystic carcinoma treated with amivantamab.	Up to 27 months
Number of Participants With Adverse Events	To determine safety of amivantamab in patients with recurrent and metastatic adenoid cystic carcinoma as measured by CTCAE v5. Any subject that had at least one adverse event will be counted.	Up to 16 months regardless of attribution should be collected continuously during the treatment period and for a minimum of 30 days following the last dose of study treatment.

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With a Genetic Mutation	To determine the molecular signatures of response and resistance to amivantamab via molecular signatures of response and resistance- measured by comprehensive analysis of Transcriptome Sequencing	2 years
Quality of Life - Measured Via FACT-HN	The FACT HN is a patient reported outcome (PRO) measure that assesses health related quality of life in patients with head and neck cancer. It evaluates general cancer related quality of life as well as symptoms and concerns specific to head and neck cancer. The total score range is 0 - 144, with higher scores reflecting more positive perceptions across areas of well-being. A difference score from end of treatment and pre-treatment was calculated.	2 years

Collaborators and Investigators

• Sponsor: Trisha Wise-Draper
• Investigators: Principal Investigator: Trisha Wise-Draper, MD, PhD, University of Cincinnati

Publications and helpful links

General Publications

• Hanna GJ, Zamulko OY, Grover P, Adkins DR, Oppelt PJ, Romano AE, Lehn MA, Bachmann LM, Wikenheiser-Brokamp KA, Lemmon CA, Forsythe AJ, Allen CL, Pan J, Rai SN, El-Gamal D, Wise-Draper TM. Amivantamab for Recurrent or Metastatic Adenoid Cystic Carcinoma: A Phase 2 Nonrandomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2026 Apr 1;152(4):376-383. doi: 10.1001/jamaoto.2025.5404.

Study record dates

Study Major Dates

• Study Start (Actual): August 5, 2022
• Primary Completion (Actual): March 2, 2026
• Study Completion (Estimated): August 5, 2028

Study Registration Dates

• First Submitted: September 15, 2021
• First Submitted That Met QC Criteria: September 29, 2021
• First Posted (Actual): October 12, 2021

Study Record Updates

• Last Update Posted (Actual): May 8, 2026
• Last Update Submitted That Met QC Criteria: May 5, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Keywords: Amivantamab; Salivary Gland Cancer; Adenoid cystic carcinoma
• Additional Relevant MeSH Terms: Mouth Diseases; Stomatognathic Diseases; Neoplasms by Site; Neoplasms; Neoplasms by Histologic Type; Head and Neck Neoplasms; Neoplasms, Glandular and Epithelial; Adenocarcinoma; Carcinoma; Salivary Gland Diseases; Mouth Neoplasms; Carcinoma, Adenoid Cystic; Salivary Gland Neoplasms; Antineoplastic Agents, Immunological; Antineoplastic Agents; amivantamab
• Other Study ID Numbers: UCCC-HN-21-02

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No